Zeeshan Fazal

Bioinformatics Computational Genomic Specialist, (Clinical)

Designed and deployed robust WES/WGS pipelines for somatic and germline variant analysis in rare diseases. Performed bulk and single-cell RNA-seq analyses, including clustering, differential expression, and pathway enrichment. Integrated multi-omics datasets (genomics, transcriptomics, epigenomics) to refine disease phenotyping and identify biomarkers. Developed a comprehensive mtDNA variant workflow with heteroplasmy estimation and clinical annotation. Automated pipelines using Snakemake and cloud infrastructure for scalable, high-throughput analysis. Collaborated with clinicians and researchers to deliver actionable insights for clinical genomics studies.

Bioinformatics Scientist

Developed advanced bioinformatics workflows for CAR-T and NK cell immunotherapy programs, supporting target discovery and translational research. Built pipelines to identify tumor-specific antigens using single-cell and bulk RNA-seq, surfaceome data, and public datasets. Evaluated engineered cell therapy platforms through multi-dimensional analysis of transgene expression, persistence, and cytotoxicity. Generated disease-specific molecular signatures and applied ML for biomarker discovery and phenotype classification. Applied cutting-edge single-cell RNA-seq to study tumor heterogeneity, immune profiling, and treatment response.

Bioinformatics Postdoc/Research Scientist

Investigated cisplatin sensitivity and resistance in testicular germ cell tumors (TGCTs) using integrative multi-omics approaches. Performed RNA-seq analysis to identify transcriptional signatures linked to chemotherapy response. Analyzed ChIP-seq and DNA methylation data to explore epigenetic regulation of drug resistance. Applied Gene Set Enrichment Analysis (GSEA) to uncover dysregulated biological pathways. Conducted comparative analysis using public datasets (TCGA, GEO) to validate findings and identify biomarkers. Integrated genomic and epigenomic data to reveal regulatory mechanisms and potential therapeutic targets in TGCTs.

University of Illinois at Urbana-Champaign